Home › Research › Treatments
Development of a novel anti‐amyloid therapeutic: an orally administrable anti‐abeta‐oligomer compound in early preventative intervention
Hedi Zhou, Adeola Shobo, Mark A. Hancock, Fatima El Ansari, Sara Touj, Medhinee M. Malvankar, Pei You Wu, Louis-Charles Masson et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Orally dosed D-AIP possessed favourable biostability, pharmacokinetics, and brain region distribution. Notably, (i) D-AIP forms heteromeric complexes with toxic Aβ oligomers in the brains of 3xTg-AD animals, (ii) attenuated plaque amyloid pathology and (iii) attenuated neuroinflammation at the lag-phase of amyloid aggregation in male and female 3xTg mice. Additionally, behaviour and structural analysis showed that D-AIP treatment had no adverse effects on memory and cognition. Our findings demonstrate that oral administrated D-AIP effectively targeted Aβ oligomers to prevent AD-associated deposition and neurotoxicity in an AD mouse model at very early stages of amyloid deposition. Since orally delivered D-AIP had no observable adverse effect it presents great promise as a next-generation AD therapeutic.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhou, H., Shobo, A., Hancock, M. A., El Ansari, F., Touj, S., Malvankar, M. M., et al. (2025). Development of a novel anti‐amyloid therapeutic: an orally administrable anti‐abeta‐oligomer compound in early preventative intervention. Alzheimer s & Dementia. https://doi.org/10.1002/alz70859_101967
Vancouver
Zhou H, Shobo A, Hancock MA, El Ansari F, Touj S, Malvankar MM, et al. Development of a novel anti‐amyloid therapeutic: an orally administrable anti‐abeta‐oligomer compound in early preventative intervention. Alzheimer s & Dementia. 2025. doi:10.1002/alz70859_101967. PMID: 41448821.
BibTeX
@article{zhou2025-41448821,
author = {Zhou, Hedi and Shobo, Adeola and Hancock, Mark A. and El Ansari, Fatima and Touj, Sara and Malvankar, Medhinee M. and Wu, Pei You and Masson, Louis-Charles and others},
title = {{Development of a novel anti‐amyloid therapeutic: an orally administrable anti‐abeta‐oligomer compound in early preventative intervention}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70859_101967},
pmid = {41448821},
url = {https://doi.org/10.1002/alz70859_101967}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Orally dosed D-AIP possessed favourable biostability, pharmacokinetics, and brain region distribution.
- Notably, (i) D-AIP forms heteromeric complexes with toxic Aβ oligomers in the brains of 3xTg-AD animals, (ii) attenuated plaque amyloid pathology and (iii) attenuated neuroinflammation at the lag-phase of amyloid aggregation in male and female 3xTg mice.
- Additionally, behaviour and structural analysis showed that D-AIP treatment had no adverse effects on memory and cognition.
- Our findings demonstrate that oral administrated D-AIP effectively targeted Aβ oligomers to prevent AD-associated deposition and neurotoxicity in an AD mouse model at very early stages of amyloid deposition.
- Since orally delivered D-AIP had no observable adverse effect it presents great promise as a next-generation AD therapeutic.
Why it matters
In an Alzheimer's mouse model at very early stages of amyloid deposition, orally given D-AIP targeted toxic Aβ oligomers, reduced plaque amyloid pathology and neuroinflammation, and showed no adverse effects on memory and cognition. These findings are from animal and laboratory work, so it is not yet known whether the compound would work or be safe in people.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 32/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Gerhard Multhaup: h-index 23 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | McGill University: institution h-index 1,373 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41448821) |
| Free to read | 2 / 2 | Free to read |
| Total | 32 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70859_101967
- PubMed: 41448821
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.